Amylyx Pharmaceuticals (AMLX) Capital Expenditures (2021 - 2025)

Amylyx Pharmaceuticals' Capital Expenditures history runs 5 years deep, the most recent figure standing at $86000.0 for Q4 2025.

• In Q4 2025, Capital Expenditures rose 330.0% year-over-year to $86000.0; the TTM figure through Dec 2025 stood at $138000.0 (down 12.1% YoY), while the FY2025 annual figure was $138000.0, down 12.1% from the prior year.
• Capital Expenditures was $86000.0 for Q4 2025 at Amylyx Pharmaceuticals, up from $24000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q2 2022 to a low of -$19000.0 in Q3 2024.
• Historically, Capital Expenditures has averaged $232368.4 across 5 years, with a median of $153000.0 in 2021.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures soared 2342.86% in 2022, then sank 105.32% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $186000.0 in 2021, then jumped by 233.33% to $620000.0 in 2022, then slumped by 42.58% to $356000.0 in 2023, then plunged by 94.38% to $20000.0 in 2024, then jumped by 330.0% to $86000.0 in 2025.
• The last three Capital Expenditures figures came in at $86000.0 (Q4 2025), $24000.0 (Q3 2025), and $17000.0 (Q2 2025), per Business Quant data.